Navigation Links
Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
Date:9/5/2012

EAST BRUNSWICK, N.J., Sept. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Louis Ferrari, President and Chief Executive Officer of Savient, will present at the 6th Annual Imperial Capital Global Opportunities Conference on Thursday, September 20th at 10:30am Eastern Time at the Waldorf=Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVN
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
2. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
3. Savient Pharmaceuticals Adopts Stockholder Rights Plan
4. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
5. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
6. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
7. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Questcor Pharmaceuticals to Present at Investor Conferences in September
10. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
11. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Va. , Feb. 27, 2015 ... confident or very confident substituting an interchangeable biosimilar ... products share the same nonproprietary name, according to ... Care Pharmacy,s (AMCP,s) Journal of Managed Care ... only about 25 percent of pharmacists would feel ...
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... study published in the Proceedings of the ... that showed when ibrutinib (IMBRUVICA ® ) was ... suppression of tumor growth was enhanced suggesting a ... hematologic cancers and solid tumors with the combination. ...
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
(Date:2/28/2015)... (PRWEB) February 28, 2015 The noted ... announce that they have officially relaunched their website. The ... user-friendly, but it contains a new section about their ... to read the full biographies of each Friedman Dental ... of the website was designed to provide our patients ...
(Date:2/28/2015)... Viejo, California (PRWEB) February 28, 2015 Developers ... the release of a new overlay plugin for Final Cut ... Film Studios. , “FCPX Overlay Chromatic gives users total control ... said Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay ... maintaining an easy to use interface.” , FCPX Overlay Chromatic ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
(Date:2/28/2015)... 2015 My Shiney Hiney® LLC., the renowned ... to Las Vegas, Nevada for the annual ASD Market Week ... the leading consumer-goods tradeshows and My Shiney Hiney will be ... My Shiney Hiney can be found at booth number C1663. ... the at-home personal hygiene brush and cleansing system exclusively created ...
Breaking Medicine News(10 mins):Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2
... ... used learn how African health care providers are collaborating with physicians from Johns Hopkins ... Africa. , ... Maryland (PRWEB) September 8, 2009 -- The recent tragic death of Michael Jackson has ...
... moths and fruit flies, react to microbial infection in the ... test the efficiency of new drugs, thereby reducing the need ... of Ireland Maynooth, presented his research findings at the ... today (8 September). Neutrophils, which are a type of ...
... loss as much as 10-fold, researchers find, , MONDAY, ... disease, even a minor infection can double the rate ... new study, researchers found that Alzheimer,s patients who had ... and bruises -- can have high levels of tumor ...
... LONDON, September 7 Regurin(R) XL (trospium chloride), a,once-daily, ... been launched in the UK. Regurin(R) XL provides rapid,significant ... has a,reduced potential for central nervous system (CNS) side ... as irritable bladder, is a condition that results from,sudden, ...
... a grant totaling more than a million dollars for John ... Director of the Robarts Research Institute at The University of ... you have a very high risk of developing Alzheimer,s disease ... huge toll on society and costing billions of dollars in ...
... ATSU ... , ... September 6, 2009 -- More than 200 community members and health professionals gathered at ... Valley and celebrate the beginning of the hospital,s relationship with A.T. Still University ...
Cached Medicine News:Health News:Medical Student Wins Travel Scholarship to Kenya to Study Operative Care in Africa 2Health News:Medical Student Wins Travel Scholarship to Kenya to Study Operative Care in Africa 3Health News:Even Mild Infections Hasten Decline With Alzheimer's 2Health News:Even Mild Infections Hasten Decline With Alzheimer's 3Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 2Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 3Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 4Health News:REGURIN(R) XL (trospium chloride) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder 5Health News:Million dollar boost to Alzheimer's and stroke research at Robarts 2Health News:ATSU Arizona Health & Technology Park Partner HealthSouth Holds Grand Opening 2
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
The Knotless Anchor, a titanium alloy implant, is used for soft tissue reattachment to bone. The Knotless Anchor is indicated for open and arthroscopic Bankart repairs....
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... MiniMite Suture Anchor System is ... market that will accept two ... until deployed eliminates tissue, bone ... ultra smooth eyelet hole preserves ...
Medicine Products: